drugset / Trial / NCT01787357

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) on electrocardiogram results (recordings of the electrical activity of the heart) in healthy volunteers after a single therapeutic dose (300 mg) and a single supra-therapeutic dose (4 times higher \[1,200 mg\] than the anticipated therapeutic dose of 300 mg). The safety and tolerability of canagliflozin will also be assessed.

Timeline

Start
2008-06
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 1200 mg Oral
Subject Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.